AMYRIS TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTH CARE CONFERENCE

Amyris, a synthetic biotechnology company (Nasdaq: AMRS), will present at the 41st Annual J.P.

Rhea-AI Summary

Amyris, a synthetic biotechnology company (Nasdaq: AMRS), will present at the 41st Annual J.P. Morgan Health Care Conference on January 11, 2023, at 11:15 am PT in San Francisco. This event showcases Amyris's focus on sustainable consumption through its Lab-to-Market™ technology. A live webcast and replay will be accessible via the company's Investor Relations section. Amyris specializes in creating sustainable ingredients for health, beauty, and flavor markets, reaching over 300 million consumers globally.

Argus Session date unavailable

-4.83% session move Open Argus

Details

News Market Reaction – AMRS

The recorded move for AMRS in the trading session of this news was -4.83%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EMERYVILLE, Calif., Jan. 4, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform today announced that management will present at the 41st Annual J.P. Morgan Health Care Conference on Wednesday, January 11, 2023, at 11:15 am PT (2:15 pm ET) in San Francisco.

A live webcast of the presentation and a replay will be available on the Investor Relations section of the company's website at https://investors.amyris.com/events-and-presentations.

About Amyris

Amyris (Nasdaq: AMRS) is a leading synthetic biotechnology company, transitioning the Clean Health & Beauty and Flavors & Fragrances markets to sustainable ingredients through fermentation and the company's proprietary Lab-to-Market™ technology platform. This Amyris platform leverages state-of-the-art machine learning, robotics and artificial intelligence, enabling the company to rapidly bring new innovation to market at commercial scale. Amyris ingredients are included in over 20,000 products from the world's top brands, reaching more than 300 million consumers. Amyris also owns and operates a family of consumer brands that is constantly evolving to meet the growing demand for sustainable, effective and accessible products. For more information, please visit http://www.amyris.com. 

Amyris, the Amyris logo, and, Lab-to-Market are trademarks or registered trademarks of Amyris, Inc. or its subsidiaries in the U.S. and/or other countries.

Investor Contact: 
Amyris, Inc. 
Paul Vincent 
vincent@amyris.com 
+1 (510) 450-0761

Argot Partners 
Jason Finkelstein 
amyris@argotpartners.com 
+1 (212) 600-1902

Media Contact: 
Amyris, Inc. 
Lauren White 
lwhite@amyris.com 
+1 (202) 320-8677

View original content to download multimedia:https://www.prnewswire.com/news-releases/amyris-to-present-at-the-41st-annual-jp-morgan-health-care-conference-301712827.html

SOURCE Amyris, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Amyris present at the J.P. Morgan Health Care Conference?

Amyris will present on January 11, 2023, at 11:15 am PT.

Where can I watch the Amyris presentation at the J.P. Morgan Conference?

The presentation will be available as a live webcast and replay on the Investor Relations section of Amyris's website.

What is the significance of the Lab-to-Market technology for AMRS?

Lab-to-Market technology allows Amyris to develop sustainable ingredients quickly for health and beauty markets.

How many consumers do Amyris products reach?

Amyris products reach over 300 million consumers worldwide.

What conference is Amyris participating in January 2023?

Amyris is participating in the 41st Annual J.P. Morgan Health Care Conference.